Abstract
Glioblastoma frequently exhibits therapy-associated subtype transitions to mesenchymal phenotypes with adverse prognosis. Here, we perform multi-omic profiling of 60 glioblastoma primary tumours and use orthogonal analysis of chromatin and RNA-derived gene regulatory networks to identify 38 subtype master regulators, whose cell population-specific activities we further map in published single-cell RNA sequencing data. These analyses identify the oligodendrocyte precursor marker and chromatin modifier SOX10 as a master regulator in RTK I-subtype tumours. In vitro functional studies demonstrate that SOX10 loss causes a subtype switch analogous to the proneural-mesenchymal transition observed in patients at the transcriptomic, epigenetic and phenotypic levels. SOX10 repression in an in vivo syngeneic graft glioblastoma mouse model results in increased tumour invasion, immune cell infiltration and significantly reduced survival, reminiscent of progressive human glioblastoma. These results identify SOX10 as a bona fide master regulator of the RTK I subtype, with both tumour cell-intrinsic and microenvironmental effects.
Introduction
Glioblastoma (GBM) is a notoriously heterogeneous and aggressive brain cancer. Clinicians categorize these tumors into four molecular subtypes: IDH-mutant, Mesenchymal (MES), RTK I (proneural-like), and RTK II (classical-like). A major challenge in GBM therapy is "subtype switching," particularly the transition from the RTK I subtype to the highly invasive and treatment-resistant MES subtype following therapy. Understanding the "master regulators"—transcription factors that act as control knobs for these cellular states—is essential for deciphering the mechanisms behind these transitions.
Multi-omic Mapping of the GBM Landscape
To identify the drivers of subtype identity, researchers performed an extensive multi-omic analysis of 60 primary human glioblastoma tumors. This study integrated whole-genome bisulfite sequencing (WGBS), ChIP-seq for histone modifications, ATAC-seq for chromatin accessibility, and total RNA sequencing to map the regulatory landscape.
The cohort was characterized by diverse genetic alterations, including IDH1/2 mutations and various chromosomal gains/losses (e.g., Chr7 gain, Chr10 loss), which correlate with specific molecular subtypes. By mapping DNA methylation and chromatin states across the genome, the team observed that while gene promoters remain relatively stable across subtypes, distal enhancers are highly variable and serve as the primary determinants of subtype identity.
Identification of Master Regulators
Using VIPER analysis and Core Regulatory Circuit (CRC) mapping, the study identified a consensus list of 38 master regulators. These transcription factors form self-reinforcing loops that maintain specific cellular states. One of the most prominent findings was the identification of SOX10 as a master regulator for the RTK I subtype.
As shown in the profiling of the MYT1 locus (an example of a subtype-specific gene), DNA methylation and chromatin states vary significantly between subtypes. In RTK I and IDH-mutant tumors, specific regions exhibit lower methylation and active chromatin marks compared to the MES subtype, mirroring the expression patterns of subtype-defining genes.
SOX10 Loss Drives the Mesenchymal Transition
Functional validation using CRISPRi and shRNA demonstrated that SOX10 is not merely a marker but a functional anchor for the RTK I state. Loss of SOX10 triggered a global remodeling of the epigenome. ATAC-seq revealed that 89% of SOX10 binding sites lost accessibility upon its knockdown, while new regions enriched for mesenchymal motifs (e.g., RUNX, FOSL2) became accessible.
This epigenetic "re-wiring" resulted in a phenotypic switch: RTK I cells adopted mesenchymal gene signatures and became significantly more invasive. In vivo, SOX10 repression in a syngeneic mouse model led to a 40% reduction in median survival, dropping from 104 days to just 63 days, accompanied by increased immune cell infiltration in the tumor microenvironment.
Conclusion and Future Directions
This study establishes SOX10 as a critical regulator of glioblastoma subtype identity. Its loss facilitates a transition to the aggressive MES phenotype through large-scale epigenetic remodeling and microenvironmental changes. While this work highlights SOX10, the roles of the other 37 identified master regulators remain to be fully explored. Future research will investigate whether targeting these regulatory circuits or the associated epigenetic machinery can prevent the deadly mesenchymal transition in patients.
Summary updated